Kevin Conroy, Chairman and CEO of Exact Sciences, shared a post on LinkedIn:
“In Q2, the Exact Sciences team delivered 1.3 million test results, an all-time high, helping more people get the answers they need to make life-changing decisions.
We secured Medicare coverage in colorectal cancer for Oncodetect, our molecular residual disease test, and saw strong performance across Screening, Precision Oncology, and new launches. These achievements drove $811M in total revenue and led us to raise our full-year 2025 guidance.
We also announced an exclusive license agreement with Freenome to offer a blood-based colorectal cancer screening test, pending regulatory approval.
More posts featuring Kevin Conroy.